Pyrrolidine Compounds for Targeted Lp(a) Plasma Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmaceutical treatments to lower elevated lipoprotein(a) (Lp(a)) levels, as current therapies are inadequate for managing cardiovascular disease risks associated with this lipid disorder, particularly since Lp(a) levels are not significantly affected by diet or exercise and there are few approved treatment options.
Innovation Solution
Development of pyrrolidine compounds and their pharmaceutically acceptable salts, which can be administered to reduce Lp(a) plasma levels, potentially offering a new therapeutic approach for cardiovascular diseases, especially for patients with elevated Lp(a) concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If apheresis is used to filter blood to remove LDL and Lp(a), then Lp(a) levels are reduced temporarily, but the effects are temporary and need to be repeated every two weeks
Solution Approach 1:
The patent replaces the mechanical apheresis system with a pharmaceutical compound (pyrrolidine derivative) that chemically inhibits Lp(a) production. This substitution transforms a temporary mechanical filtration process into a sustained chemical therapy that continuously lowers Lp(a) levels without repeated interventions.
Solution Approach 2:
The patent changes the approach from physical removal (apheresis) to biochemical inhibition by introducing a pharmaceutical compound that modifies the metabolic parameters of Lp(a) production. This parameter change enables continuous reduction of Lp(a) levels rather than periodic removal.
2Adaptability or versatility
If current standard of care therapies (statins, fibrates, niacin) are used, then LDL-c, HDL-c, and triglycerides are managed, but Lp(a) levels are not significantly affected
Solution Approach 1:
The patent segments the lipid disorder treatment approach by identifying Lp(a) as a distinct target separate from traditional LDL-c, HDL-c, and triglyceride management. This segmentation allows for specialized therapy (pyrrolidine compound) that specifically addresses Lp(a) without relying on non-effective standard therapies.
Solution Approach 2:
The patent introduces a novel intermediary substance (pyrrolidine compound) that acts as a mediator between the patient's lipid metabolism and Lp(a) reduction. This intermediary provides a new therapeutic mechanism that fills the gap left by standard of care therapies that cannot effectively lower Lp(a).
3Reliability
If there are few approved treatment options for elevated Lp(a), then treatment accessibility is limited, but the need for effective Lp(a) reduction remains critical
Solution Approach 1:
The patent changes the therapeutic parameter space by developing a novel pyrrolidine compound with specific chemical structures (Formula I and Formula II) that target Lp(a) production mechanisms. This parameter change creates a new effective treatment option rather than modifying existing ineffective therapies.
Solution Approach 2:
The patent employs composite chemical structures in the pyrrolidine compounds, combining specific functional groups and molecular configurations to achieve optimal Lp(a) reduction. This composite approach enables the development of a new effective treatment class that expands therapeutic options.
Data Source
AI summary
The present invention provides compounds of the Formulaor a pharmaceutically acceptable salt thereof, and compounds processes for preparing the compounds and their salts, and a pharmaceutical composition.